JP2023061448A - 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品 - Google Patents

小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品 Download PDF

Info

Publication number
JP2023061448A
JP2023061448A JP2021171332A JP2021171332A JP2023061448A JP 2023061448 A JP2023061448 A JP 2023061448A JP 2021171332 A JP2021171332 A JP 2021171332A JP 2021171332 A JP2021171332 A JP 2021171332A JP 2023061448 A JP2023061448 A JP 2023061448A
Authority
JP
Japan
Prior art keywords
endoplasmic reticulum
triglyceride
reticulum stress
formula
food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021171332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023061448A5 (https=
Inventor
誠 坪井
Makoto Tsuboi
泰子 阪田
Yasuko Sakata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Refine Holdings Co Ltd
Original Assignee
Refine Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Refine Holdings Co Ltd filed Critical Refine Holdings Co Ltd
Priority to JP2021171332A priority Critical patent/JP2023061448A/ja
Priority to US18/702,472 priority patent/US20240415797A1/en
Priority to PCT/JP2022/038842 priority patent/WO2023068285A1/ja
Publication of JP2023061448A publication Critical patent/JP2023061448A/ja
Publication of JP2023061448A5 publication Critical patent/JP2023061448A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2021171332A 2021-10-20 2021-10-20 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品 Pending JP2023061448A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021171332A JP2023061448A (ja) 2021-10-20 2021-10-20 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品
US18/702,472 US20240415797A1 (en) 2021-10-20 2022-10-19 Endoplasmic reticulum stress inhibitor, neurodegenerative disease preventing/improving agent, agent for prevention/progression prevention/improvement of dementia, and food product
PCT/JP2022/038842 WO2023068285A1 (ja) 2021-10-20 2022-10-19 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2021171332A JP2023061448A (ja) 2021-10-20 2021-10-20 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品

Publications (2)

Publication Number Publication Date
JP2023061448A true JP2023061448A (ja) 2023-05-02
JP2023061448A5 JP2023061448A5 (https=) 2024-10-28

Family

ID=86059189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021171332A Pending JP2023061448A (ja) 2021-10-20 2021-10-20 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品

Country Status (3)

Country Link
US (1) US20240415797A1 (https=)
JP (1) JP2023061448A (https=)
WO (1) WO2023068285A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117298087A (zh) * 2023-10-17 2023-12-29 张岳峰 促血液药物颅内转运合剂及其应用
WO2025127147A1 (ja) * 2023-12-15 2025-06-19 リファインホールディングス株式会社 疲労回復剤、抗疲労作用剤および疲労回復用飲食物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019052629A1 (en) * 2017-09-12 2019-03-21 Sunregen Healthcare Ag LIPIDS HAVING AN IMPERATIVE NUMBER OF CARBON ATOMS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION OR FOOD SUPPLEMENT
JP2019518034A (ja) * 2016-06-08 2019-06-27 サンレーゲン ヘルスケア アーゲー 奇数個の炭素原子を有する脂質及び医薬組成物又は栄養補助食品としてのそれらの使用
WO2020054804A1 (ja) * 2018-09-13 2020-03-19 リファインホールディングス株式会社 奇数脂肪酸エステルの製造方法及び培養組成物
JP2020533019A (ja) * 2017-08-23 2020-11-19 シンプロミクス・リミテッド 制御可能なイントロンを用いる発現調節
WO2021020514A1 (ja) * 2019-07-31 2021-02-04 リファインホールディングス株式会社 コラーゲン産生促進剤、シワ改善剤、皮膚外用剤および美容飲食品
WO2021107084A1 (ja) * 2019-11-27 2021-06-03 リファインホールディングス株式会社 インスリン分泌促進剤並びにこれを用いた血糖値改善剤、糖尿病改善剤及び食品

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019518034A (ja) * 2016-06-08 2019-06-27 サンレーゲン ヘルスケア アーゲー 奇数個の炭素原子を有する脂質及び医薬組成物又は栄養補助食品としてのそれらの使用
JP2020533019A (ja) * 2017-08-23 2020-11-19 シンプロミクス・リミテッド 制御可能なイントロンを用いる発現調節
WO2019052629A1 (en) * 2017-09-12 2019-03-21 Sunregen Healthcare Ag LIPIDS HAVING AN IMPERATIVE NUMBER OF CARBON ATOMS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION OR FOOD SUPPLEMENT
WO2020054804A1 (ja) * 2018-09-13 2020-03-19 リファインホールディングス株式会社 奇数脂肪酸エステルの製造方法及び培養組成物
WO2021020514A1 (ja) * 2019-07-31 2021-02-04 リファインホールディングス株式会社 コラーゲン産生促進剤、シワ改善剤、皮膚外用剤および美容飲食品
WO2021107084A1 (ja) * 2019-11-27 2021-06-03 リファインホールディングス株式会社 インスリン分泌促進剤並びにこれを用いた血糖値改善剤、糖尿病改善剤及び食品

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BATRAKOV, S. G. ET AL.: "Characterization of the molecular species of natural lipids by metastable ion mass spectra. I. Trigl", BIOORGANICHESKAYA KHIMIYA, vol. 4, no. 9, JPN6020035867, 1978, pages 1220 - 1231, ISSN: 0005732114 *
BOUREBABA, L. ET AL.: "Cladophora glomerata methanolic extract decreases oxidative stress and improves viability and mitoch", BIOMEDICINE & PHARMACOTHERAPY, vol. 111, JPN6023001222, 2019, pages 6 - 18, ISSN: 0005732120 *
LIPIDS, vol. 46, JPN6025003636, 2011, pages 781 - 788, ISSN: 0005732115 *
MARYCZ, K. ET AL.: "The Cladophora glomerata Enriched by Biosorption Process in Cr(III) Improves Viability, and Reduces", MAR. DRUGS, vol. 15, JPN7023000120, 2017, pages 1 - 18, ISSN: 0005732119 *
SASAKI, K. ET AL.: "Microalgae Aurantiochytrium Sp. Increases Neurogenesis and Improves Spatial Learning and Memory in S", FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, vol. Vol. 8, Article 600575, JPN7023000118, February 2021 (2021-02-01), pages 1 - 14, ISSN: 0005732117 *
WANG, F. ET AL.: "Antidiabetic Activity and Chemical Composition of Sanbai Melon Seed Oil", EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. Vol.2018, Article ID 5434156, JPN7023000119, 2018, pages 1 - 14, ISSN: 0005732118 *
金本聡自、今泉和則: "小胞体ストレスと疾患", 生化学, vol. 90, no. 1, JPN6025046304, pages 51 - 59, ISSN: 0005732116 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117298087A (zh) * 2023-10-17 2023-12-29 张岳峰 促血液药物颅内转运合剂及其应用
WO2025127147A1 (ja) * 2023-12-15 2025-06-19 リファインホールディングス株式会社 疲労回復剤、抗疲労作用剤および疲労回復用飲食物

Also Published As

Publication number Publication date
WO2023068285A1 (ja) 2023-04-27
US20240415797A1 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
JP6705599B2 (ja) エイコサペンタエン酸生成微生物、脂肪酸組成物、ならびにそれらを作る方法およびそれらの使用
Kannan et al. Microbial production of omega‐3 fatty acids: an overview
JP5762393B2 (ja) ヤブレツボカビ、脂肪酸組成物、ならびにその作出および使用の方法
AU2012285806B2 (en) Fatty acid compositions
JP7685134B2 (ja) インスリン分泌促進剤並びにこれを用いた血糖値改善剤、糖尿病改善剤及び食品
KR20140019840A (ko) 스키조키트리움 종의 돌연변이유발 방법 및 이의 생성되는 변이체 균주
WO2023068285A1 (ja) 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品
JP2007008863A (ja) 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
JP2015096494A (ja) 生体内酸化還元状態改善剤
JP2016172770A (ja) 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
JP4040069B2 (ja) 脳機能改善用組成物
JP2024176004A (ja) 小胞体ストレス抑制剤、慢性腎臓病疾患予防改善剤および食品
US20260060952A1 (en) Prophylactic, Progression Inhibitor, Ameliorant for Visual Field Defect Disorders, Light-Induced Ocular Tissue Disorders and Related Disorders, and Food Product
WO2025127147A1 (ja) 疲労回復剤、抗疲労作用剤および疲労回復用飲食物
JP5496163B2 (ja) 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JP2014152118A (ja) 老化抑制剤
US20100028465A1 (en) Composition for ameliorating cerebral function
CN104988078B (zh) 破囊壶菌、脂肪酸组合物和其制备方法及用途
JP2025115705A (ja) 炎症性サイトカイン抑制剤
JP6938163B2 (ja) 脂質組成物、その用途及びその製造方法
JP2014205710A (ja) 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
HK1241413A (en) Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
HK40013094A (en) Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
HK1166514B (en) Thraustochytrids, fatty acid compositions, and methods of making and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260317